Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 8.3% | 4.2% | -4.8% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 34.9% | 39.5% | 36.8% | 36% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -0% | 15.4% | 14.4% | 10.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 0.3% | 3.1% | 1.8% | -4.3% |
| EPS | 0.008 | 0.071 | 0.039 | -0.1 |
| % Growth | -89.5% | 82.1% | 139.2% | – |
| EPS Diluted | 0.008 | 0.07 | 0.038 | -0.1 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 14.2% | 24.4% | 22.2% | 15.4% |